Bluebird bio Inc [BLUE] stock prices are down -7.91% to $8.50 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The BLUE shares have gain 34.07% over the last week, with a monthly amount glided 40.26%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Bluebird bio Inc [NASDAQ: BLUE] stock has seen the most recent analyst activity on November 15, 2024, when JP Morgan downgraded its rating to a Underweight. Previously, BofA Securities downgraded its rating to Neutral on November 15, 2024, and dropped its price target to $0.50. On August 15, 2024, downgrade downgraded it’s rating to Neutral. HSBC Securities downgraded its rating to a Reduce. Morgan Stanley upgraded its rating to a Equal-Weight and raised its price target to $7 on December 08, 2023. In a note dated September 06, 2023, HSBC Securities initiated an Buy rating and provided a target price of $4.21 on this stock.
The stock price of Bluebird bio Inc [BLUE] has been fluctuating between $5.80 and $38.40 over the past year. Currently, Wall Street analysts expect the stock to reach $13.69 within the next 12 months. Bluebird bio Inc [NASDAQ: BLUE] shares were valued at $8.50 at the most recent close of the market. An investor can expect a potential return of 61.06% based on the average BLUE price forecast.
Analyzing the BLUE fundamentals
The Bluebird bio Inc [NASDAQ:BLUE] reported sales of 53.12M for trailing twelve months, representing a drop of -14.36%. Gross Profit Margin for this corporation currently stands at -0.43% with Operating Profit Margin at -5.96%, Pretax Profit Margin comes in at -5.66%, and Net Profit Margin reading is -5.66%. To continue investigating profitability, this company’s Return on Assets is posted at -0.65, Equity is -3.22 and Total Capital is -1.87. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-12.2.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 7.69 points at the first support level, and at 6.89 for the second support level. However, for the 1st resistance point, the stock is sitting at 9.55, and for the 2nd resistance point, it is at 10.61.
Ratios To Look Out For
It’s worth pointing out that Bluebird bio Inc [NASDAQ:BLUE]’s Current Ratio is 0.51. On the other hand, the Quick Ratio is 0.33, and the Cash Ratio is 0.24. Considering the valuation of this stock, the price to sales ratio is 1.43.
Transactions by insiders
Recent insider trading involved Obenshain Andrew, President and CEO, that happened on Dec 10 ’24 when 971.0 shares were sold. Chief Medical Officer, Colvin Richard A completed a deal on Dec 10 ’24 to sell 2824.0 shares. Meanwhile, Officer Colvin Richard A bought 2824.0 shares on Dec 10 ’24.
